107 filings
8-K
VYNE
VYNE Therapeutics Inc
9 May 24
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
8:00am
8-K
VYNE
VYNE Therapeutics Inc
29 Feb 24
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
8:12am
8-K
VYNE
VYNE Therapeutics Inc
3 Jan 24
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
8:15am
8-K
VYNE
VYNE Therapeutics Inc
13 Dec 23
Departure of Directors or Certain Officers
4:00pm
8-K
VYNE
VYNE Therapeutics Inc
13 Nov 23
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:46am
8-K
o50jxanljqj acg
30 Oct 23
VYNE Therapeutics Announces Private Placement of $88 Million
7:30am
8-K
jubvyn4j57f10
14 Aug 23
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8:00am
8-K
e2ewhjsq
11 May 23
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
7fy0cqi1y kz7hwzc
1 May 23
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development
8:15am
8-K
9q01 c92j
9 Mar 23
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
4:06pm
8-K
hc9zp730xb
28 Feb 23
Entry into a Material Definitive Agreement
4:32pm
8-K
or0xp9j
10 Feb 23
Material Modifications to Rights of Security Holders
5:01pm
8-K
ryzuzymnfklmzd3 9wk
17 Jan 23
Amendments to Articles of Incorporation or Bylaws
5:15pm
8-K
zcal11yv2nlyxl5hsyhp
12 Jan 23
Results of Operations and Financial Condition
5:13pm
8-K
8qbxxpu2m6nj 0xx16
10 Nov 22
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:16pm
8-K
5lh1vefe0e5m
30 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
yzv6gkhs8 fwgjwxnkfz
12 Aug 22
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
8:15am
8-K
xnq7mhnh7uuiwgrkwtyu
10 Aug 22
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
5:01pm
8-K
putof no6wffp
27 Jul 22
Regulation FD Disclosure
9:15am
8-K
hzlqe32g
17 Jun 22
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
8:15am